Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
2/6/2008
 
First Published:
7/23/2004
1.
Phase I/II Randomized Study of Vaccine Comprising Multiple Synthetic Melanoma Peptides, Montanide ISA-51, and Sargramostim (GM-CSF) in Patients With Stage IIIB, IIIC, or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI
UVACC-MEL-41
UVACC-28502, UVACC-HIC-10464, NCT00089219
Last Modified:
10/14/2008
 
First Published:
6/25/2005
2.
Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI
UVACC-HIC-11491
UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274
Last Modified:
3/3/2005
 
First Published:
7/23/2004
3.
Phase II Randomized Study of Vaccination Comprising Multiple Synthetic Melanoma Peptides and Montanide ISA-51 With Versus Without Sargramostim (GM-CSF) in Patients With Stage IIB-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
12 and over
NCI
UVACC-MEL-43
UVACC-28903, UVACC-HIC-10524, FCCC-03045, MDA-2003-0720, NCT00089193
Last Modified:
2/6/2008
 
First Published:
7/23/2004
4.
Phase II Study of Vaccine Comprising Multiple Synthetic Melanoma Peptides, Sargramostim (GM-CSF), and Montanide ISA-51 in Patients With Unresectable Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
12 and over
NCI
UVACC-MEL-42
UVACC-24802, UVACC-HIC-10049, NCT00089206
Last Modified:
7/10/2006
 
First Published:
6/25/2005
5.
Phase I Randomized Study of Adjuvant Transdermal Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) in Combination With Either Montanide ISA-51 or Dimethyl Sulfoxide With or Without Imiquimod in Patients With Resected Stage II-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
12 and over
NCI
UVACC-MEL-45
UVACC-HIC-11490, UVACC-34204, NCT00118313
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute